focus -WSS

focus

author：fashion 2025-09-28 01:30:57 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： What Mike Pence has said that could be used in a Donald Trump trial

WSS

Takeaways from AdvaMed, the largest medical devices conference

OTC birth control: A brief history of over the counter pill design

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Attacks on the drug industry will lead to fewer breakthroughs

Nick Jonas talks about managing diabetes along with his career

Microsoft strikes partnership with Duke Health to advance health AI

knowledge

focus

focus

Walensky prepares to leave CDC — and Congress — behind

Akero's treatment for NASH falls short in cirrhosis study

Guidelines to prevent youth baseball injuries need more muscle

My superpower is killing ticks

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Verily hires former Apple Health leader as chief scientific officer

Peter Hotez and the public health issue of online harassment

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Jerome Adams on the need for new antivirals for Covid

Biden calls for immediate release of Niger's president amid apparent coup

entertainment

TytoCare raises $49 million to build out AI

What the cancer research community can learn from the Covid response

What Henrietta Lacks settlement says about racism in medicine

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

hotspot

focus

entertainment

knowledge